NCT04879121 2026-04-16
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
71 trialsNCT05638295 2026-04-16
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06669572 2026-04-15
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
Phase 2 Recruiting
NCT05327010 2026-04-14
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05821556 2026-04-14
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
National Cancer Institute, Naples
Phase 2 Recruiting
NCT03907475 2026-04-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05879146 2026-04-13
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05968326 2026-04-13
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT06311214 2026-04-13
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06319378 2026-04-13
CAPSI
Section for Affective Disorders; Northern Stockholm Psychiatry
Phase 2 Recruiting
NCT06979596 2026-04-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07209111 2026-04-13
KANDLELIT-014
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06790602 2026-04-09
SWITCH
University of California, San Diego
Phase 2 Recruiting
NCT07284589 2026-04-08
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT06593522 2026-04-07
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Amgen
Phase 2 Recruiting
NCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT04449549 2026-03-27
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
NCT07483983 2026-03-27
UNLOCK ASP3082
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT05027633 2026-03-20
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06788938 2026-03-20
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT06658405 2026-03-18
HPV2
Centre Oscar Lambret
Phase 2 Recruiting
NCT06807593 2026-03-05
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06435286 2026-03-02
Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States
Baylor College of Medicine
Phase 2 Recruiting
NCT06358677 2026-02-13
FACE
University of Utah
Phase 2 Recruiting
NCT06778408 2026-02-05
HART
University of Vermont Medical Center
Phase 2 Recruiting
NCT06417190 2026-02-04
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT07381231 2026-02-02
I-APT
Samsung Medical Center
Phase 2 Recruiting
NCT05283226 2026-01-23
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma Ltd.
Phase 2 Recruiting
NCT05502315 2026-01-23
CANOPY
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06323473 2026-01-23
Maitake
The Canadian College of Naturopathic Medicine
Phase 2 Recruiting
NCT04948619 2026-01-22
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT06201884 2026-01-12
APPAHOCA-2
Centre Francois Baclesse
Phase 2 Recruiting
NCT04570943 2025-12-05
GABRINOX-ART
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT07016230 2025-11-26
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT04116541 2025-11-21
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT05977998 2025-11-19
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06246110 2025-11-12
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Eikon Therapeutics
Phase 2 Recruiting
NCT05405413 2025-10-20
CATRINA
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT05617716 2025-10-20
SPORTSMEN
University of Oklahoma
Phase 2 Recruiting
NCT04752137 2025-10-03
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Massachusetts General Hospital
Phase 2 Recruiting
NCT04614480 2025-09-22
EXOMA2
Centre Georges Francois Leclerc
Phase 2 Recruiting
NCT06831136 2025-09-10
PANCARDINAL-2
The University of Texas Health Science Center, Houston
Phase 2 Recruiting
NCT03310879 2025-09-02
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07000162 2025-08-29
LART
Azienda USL Reggio Emilia - IRCCS
Phase 2 Recruiting
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06010342 2025-07-22
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
Teligene US
Phase 2 Recruiting